In an important milestone for the treatment of hepatitis C, AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion of MAVYRET® (glecaprevir/pibrentasvir), its pangenotypic, oral, direct-acting antiviral (DAA) therapy. The new indication [Read More…]
Gilead has paused dosing in its Phase 1b studies of GS-1720 and GS-4182—two promising long-acting HIV-1 therapies after identifying tolerability issues. No serious adverse events were reported, and the company is evaluating future development pathways.
Researchers at UPMC and Penn State have developed a new mRNA vaccine platform that is more scalable and adaptable, offering rapid protection against viruses like COVID-19 and H5N1.
Roche’s Evrysdi® 5mg tablet for spinal muscular atrophy receives European Commission approval, offering a convenient, room-temperature stable treatment option for patients aged 2 and above.
Amgen has revealed ground-breaking findings from its Phase 3 DeLLphi-304 clinical trial, showing that Imdelltra® (tarlatamab-dlle) dramatically decreased the risk of death in patients with [Read More…]
Pfizer’s BRAFTOVI® combination regimen has demonstrated a 51% reduction in the risk of death and a 47% decrease in disease progression for patients with BRAF V600E-mutant metastatic colorectal cancer, according to the pivotal Phase 3 BREAKWATER trial.
GSK has halted its Phase III PIVOT-PO trial early after an independent review confirmed tebipenem HBr met its primary efficacy goal in treating complicated urinary tract infections, marking a major step forward for oral antibiotic options.
Researchers at Mass General Brigham have developed a promising nasal spray for gene therapy, aiming to deliver treatments directly to the lungs. This innovation could offer a less invasive and more effective approach for genetic lung diseases like cystic fibrosis.
GSK’s Blenrep combinations have received a positive opinion from the CHMP for treating relapsed/refractory multiple myeloma, backed by strong Phase III trial results showing improved survival outcomes.
Roche’s Susvimo® has received FDA approval for diabetic retinopathy, becoming the first continuous delivery treatment offering sustained vision benefits with just one refill every nine months. Backed by strong Phase III results, the implant provides a long-term solution for millions at risk of vision loss.
